Nonsmall cell lung cancer

European Respiratory Review

Volumn 22, Issue 127, 2013, Pages 33-36

  Sculier, Jean Paul ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Chemotherapy; Epidemiology; Lung cancer; Screening; Thoracic surgery; Tyrosine kinase inhibitor

Indexed keywords

CISPLATIN; CRIZOTINIB; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR;

ADRENAL METASTASIS; ADVANCED CANCER; AIR POLLUTION; BRAIN METASTASIS; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SCREENING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INDUCTION CHEMOTHERAPY; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; METASTASIS RESECTION; MULTIPLE CYCLE TREATMENT; OCCUPATIONAL EXPOSURE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; REVIEW; SMOKING; TERMINAL CARE;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PALLIATIVE CARE; PNEUMONECTOMY; PREDICTIVE VALUE OF TESTS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84874731471     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00007012     Document Type: Review

References (33)

1. Malvezzi M, Bertuccio P, Levi F, et al. European cancer mortality predictions for the year 2012. Ann Oncol 2012; 23: 1044-1052.
2. Moolgavkar SH, Holford TR, Levy DT, et al. Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst 2012; 104: 541-548.
3. Wild P, Gonzalez M, Bourgkard E, et al. Occupational risk factors have to be considered in the definition of high-risk lung cancer populations. Br J Cancer 2012; 106: 1346-1352.
4. Brunekreef B, Annesi-Maesano I, Ayres JG, et al. Ten principles for clean air. Eur Respir J 2012; 39: 525-528.
5. Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 2011; 306: 1865-1873.
6. Tammemagi CM, Pinsky PF, Caporaso NE, et al. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst 2011; 103: 1058-1068.
7. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409.
8. Ehmann R, Boedeker E, Friedrich U, et al. Canine scent detection in the diagnosis of lung cancer: revisiting a puzzling phenomenon. Eur Respir J 2012; 39: 669-676.
9. Fischer BM, Mortensen J, Hansen H, et al. Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial. Thorax 2011; 66: 294-300.
10. Darling GE, Maziak DE, Inculet RI, et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J Thorac Oncol 2011; 6: 1367-1372.
11. Travis WD, Brambilla E, van Schil P, et al. Paradigm shift in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur Respir J 2011; 38: 239-243.
12. Ellis PM, Blais N, Soulieres D, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol 2011; 6: 1379-1391.
13. Berghmans T, Pasleau F, Paesmans M, et al. Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. Eur Respir J 2012; 39: 9-28.
14. Whitson BA, Groth SS, Andrade RS, et al. Survival after lobectomy versus segmentectomy for stage I non-small cell lung cancer: a population-based analysis. Ann Thorac Surg 2011; 92: 1943-1950.
15. Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol 2012; 30: 172-178.
16. Boni C, Tiseo M, Boni L, et al. Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV nonsmall cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). Br J Cancer 2012; 106: 658-665.
17. Behera M, Owonikoko TK, Chen Z, et al. Single agent maintenance therapy for advanced stage non-small cell lung cancer: a metaanalysis. Lung Cancer 2012; 77: 331-338.
18. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-2874.
19. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
20. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
21. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line singleagent iressa versus gemcitabine and cisplatin trial in neversmokers with adenocarcinoma of the lung. J Clin Oncol 2012; 30: 1122-1128.
22. Gaafar RM, Surmont VF, Scagliotti GV, et al. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/ 03). Eur J Cancer 2011; 47: 2331-2340.
23. Girard N, Sima CS, Jackman DM, et al. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J 2012; 39: 366-372.
24. Leary AF, Castro DG, Nicholson AG, et al. Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors. Eur J Cancer 2012; 48: 61-67.
25. Paik JH, Choi CM, Kim H, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012; 76: 403-409.
26. Raz DJ, Lanuti M, Gaissert HC, et al. Outcomes of patients with isolated adrenal metastasis from non-small cell lung carcinoma. Ann Thorac Surg 2011; 92: 1788-1792.
27. Salah S, Tanvetyanon T, Abbasi S. Metastatectomy for extracranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases. Lung Cancer 2012; 75: 9-14.
28. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011; 6: 1496-1504.
29. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
30. Temel JS, Greer JA, Admane S, et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic nonsmall-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol 2011; 29: 2319-2326.
31. Greer JA, Pirl WF, Jackson VA, et al. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol 2012; 30: 394-400.
32. Meeussen K, Van den BL, Echteld MA, et al. End-of-Life care and circumstances of death in patients dying as a result of cancer in Belgium and the Netherlands: a retrospective comparative study. J Clin Oncol 2011; 29: 4327-4334.
33. Fang F, Fall K, Mittleman MA, et al. Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med 2012; 366: 1310-1318.